Five years' experience with iodine-125 therapy of Graves' disease.
D000328:Adult; D000368:Aged; D013956:Antithyroid Agents / Q000627:therapeutic use; D004307:Dose-Response Relationship, Radiation; D004359:Drug Therapy, Combination; D005132:Eye Manifestations; D005260:Female; D005500:Follow-Up Studies; D006111:Graves Disease / Q000097:blood / Q000188:drug therapy / Q000532:radiotherapy*; D006801:Humans; D006980:Hyperthyroidism / Q000209:etiology; D007037:Hypothyroidism / Q000209:etiology; D007457:Iodine Radioisotopes / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000627:therapeutic use; D011878:Radiotherapy / Q000009:adverse effects; D011879:Radiotherapy Dosage; D013954:Thyroglobulin / Q000097:blood; D013972:Thyrotropin / Q000097:blood; D013997:Time Factors; D014284:Triiodothyronine / Q000097:blood
D013956:Antithyroid Agents; D007457:Iodine Radioisotopes; D014284:Triiodothyronine; D013972:Thyrotropin; D013954:Thyroglobulin; D011433:Propranolol